主页文献库搜索
Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of ...

Jackman(D M),Sequist(L V),Cioffredi(L),Rui... J Clin Oncol 0000-00-00

...KRAS mutations. A total of 121 mutations in EGFR or KRAS were detected. 75 pts had a sensitizing EGFR mutation. (RR = 63...

Phase I trial of combination nab-paclitaxel and pemetrexed in advanced solid ...

Ho(C),Davies(A M),Lara(P N),Chew(H K),Beck... J Clin Oncol 0000-00-00

...KRAS mutations, p16 and APC gene promoter methylation.,Pemetrexed 500 mg/m day 1 with ABI 007 260 mg/m is feasible and w...

Preliminary activity and safety results from a phase I clinical trial of PF-0...

Janne(P A),Schellens(J H),Engelman(J A),Ec... J Clin Oncol 0000-00-00

...KRAS, within the phase I study are reported.,NSCLC pts (n=42) received PF 16 mg (n=1), 30 mg (n=2), 45 mg, the MTD (n=33...

Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment o...

Tzekova(V),Cebotaru(C),Ciuleanu(T E),Damja... J Clin Oncol 0000-00-00

...KRAS gene mutations. MEK1/2 inhibition block the Raf/MEK/ERK pathway since these kinases lie downstream of Ras, and ERK1...

KRAS status and efficacy of first-line treatment of patients with metastatic ...

Bokemeyer(C),Bondarenko(I),Hartmann(J T),D... J Clin Oncol 0000-00-00

...KRAS mutation status.,In general, the population with tissue available for KRAS analysis (n=233) was representative of t...

Relationship of efficacy with KRAS status (wild type versus mutant) in patien...

Tejpar(S),Peeters(M),Humblet(Y),Vermorken(... J Clin Oncol 0000-00-00

...KRAS mutation analysis.,In Arm A, 45 pts were randomized: 19 pts (42%) were KRAS wt, 19 pts (42%) were KRAS mt, and 7 pt...

Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) an...

Loupakis(F),Pollina(L),Stasi(I),Masi(G),Fu... J Clin Oncol 0000-00-00

...KRAS mutational status are ongoing. Final data will be presented at the meeting. Supported by A.R.C.O.,No significant fi...

Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared w...

Siena(S),Tabernero(J),Burkes(R L),Cassidy(... J Clin Oncol 0000-00-00

...KRAS mutational status in both arms as a potential biomarker for pmab activity in combination with FOLFOX as first-line ...

Role of KRAS mutation in predicting response, progression-free survival, and ...

Di Fiore(F),Van Cutsem(E),Laurent-Puig(P),... J Clin Oncol 0000-00-00

...KRAS mut was detected in 98 pts including 40/107 (37.4%) pts with SD and 58/97 (59.8%) with PD. All responders were KRAS...

Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI ...

Peeters(M),Wilson(G),Ducreux(M),Cervantes(... J Clin Oncol 0000-00-00

...KRAS mutational status in both arms as a potential biomarker for pmab activity combined with FOLFIRI. The study includes...

上一页 944 945 946 947 948 949 950 951 952 下一页 948 / 共 953

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]